BMS/Celgene Post-Merger Early R&D Strategy: Partnerships Are Still Key, Vessey Says

 
• By Mandy Jackson
  
Bristol’s Rupert Vessey
Bristol's Rupert Vessey said deal-making will continue after the Celgene merger • Source: Bristol-Myers Squibb Co.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business